<DOC>
	<DOC>NCT01834222</DOC>
	<brief_summary>The purpose of this study is to assess safety profile of Prevenar 13™ when used among Korean adults in the routine clinical setting, as required for any new drug approved by Korea Food and Drug Administration (KFDA).</brief_summary>
	<brief_title>Post Market Surveillance to Observe Safety of Prevenar13™ in Adults</brief_title>
	<detailed_description>non-randomization, non-probability sampling</detailed_description>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Korean adults aged 18 years and older; provided the conditions pertaining to contraindications, warnings, precautions, and interactions stated in the local product document do not apply. Evidence of a personally signed and dated informed consent document indicating that the subject(or a legally acceptable representative) has been informed of all pertinent aspects of the study. Subjects who are not indicated and/or contraindicated for the Prevenar13 usage will not be included.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>